| scholarly article | Q13442814 |
| P50 | author | Ángel Carracedo | Q20535757 |
| Miguel A. Piris | Q37831476 | ||
| María Villa-Morales | Q80422050 | ||
| P2093 | author name string | J Benítez | |
| B Martínez | |||
| J Fernández-Piqueras | |||
| E González-Gugel | |||
| M A Cobos | |||
| V Álvarez-Iglesias | |||
| P2860 | cites work | Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule | Q24305174 |
| Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing | Q24306732 | ||
| FADD protein release mirrors the development and aggressiveness of human non-small cell lung cancer | Q24634052 | ||
| A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency | Q27676800 | ||
| Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen | Q28115556 | ||
| FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). | Q28240752 | ||
| FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex | Q28283294 | ||
| Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family | Q28285445 | ||
| Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand | Q28513283 | ||
| Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion | Q29616531 | ||
| The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations | Q33836041 | ||
| Defining CD95 as a tumor suppressor gene | Q34042835 | ||
| Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation | Q34428954 | ||
| Regulation of T cell apoptosis during the immune response | Q34663745 | ||
| Molecular classification of T-cell lymphomas | Q37398316 | ||
| The role of FasL and Fas in health and disease. | Q37598566 | ||
| Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways. | Q37825665 | ||
| Hodgkin disease and the role of the immune system | Q37850445 | ||
| CD95-mediated cell signaling in cancer: mutations and post-translational modulations | Q37951369 | ||
| Targeting the Fas/FasL signaling pathway in cancer therapy. | Q37975245 | ||
| Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor | Q38317125 | ||
| Identification of a methylation hotspot in the death receptor Fas/CD95 in bladder cancer | Q39444571 | ||
| Reduced FAS transcription in clones of U937 cells that have acquired resistance to Fas-induced apoptosis | Q39905787 | ||
| Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma | Q40317344 | ||
| Loss of FADD protein expression results in a biased Fas-signaling pathway and correlates with the development of tumoral status in thyroid follicular cells | Q40648250 | ||
| Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations | Q44681531 | ||
| Modulation of the Fas-apoptosis-signalling pathway by functional polymorphisms at Fas, FasL and Fadd and their implication in T-cell lymphoblastic lymphoma susceptibility. | Q44844225 | ||
| Downregulation of Fas gene expression in Sézary syndrome is associated with promoter hypermethylation | Q46434131 | ||
| Haploinsufficiency, rather than the effect of an excessive production of soluble CD95 (CD95{Delta}TM), is the basis for ALPS Ia in a family with duplicated 3' splice site AG in CD95 intron 5 on one allele | Q46471351 | ||
| CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. | Q52530560 | ||
| Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence. | Q52884928 | ||
| Frequent downregulation of Fas (CD95) expression and function in melanoma. | Q53963857 | ||
| Mutation analysis of the FAS and TNFR apoptotic cascade genes in hematological malignancies. | Q54022367 | ||
| Functional Fas (Cd95/Apo-1) promoter polymorphisms in inbred mouse strains exhibiting different susceptibility to gamma-radiation-induced thymic lymphoma. | Q54630361 | ||
| Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome | Q55670225 | ||
| Prognostic relevance of altered Fas (CD95)-system in human breast cancer | Q61900217 | ||
| A role for the Fas/FasL system in modulating genetic susceptibility to T-cell lymphoblastic lymphomas | Q80422062 | ||
| Lymphoblastic lymphoma | Q83312861 | ||
| P4510 | describes a project that uses | ImageQuant | Q112270642 |
| P921 | main subject | lymphoblastic lymphoma | Q6708247 |
| P304 | page(s) | e1110 | |
| P577 | publication date | 2014-03-06 | |
| P1433 | published in | Cell Death and Disease | Q2197222 |
| P1476 | title | FAS system deregulation in T-cell lymphoblastic lymphoma | |
| P478 | volume | 5 |
| Q39655215 | Analysis of PI3K pathway components in human cancers. |
| Q37641627 | Deregulated FADD expression and phosphorylation in T-cell lymphoblastic lymphoma. |
| Q89254435 | Electroacupuncture Inhibits Apoptosis of Peri-Ischemic Regions via Modulating p38, Extracellular Signal-Regulated Kinase (ERK1/2), and c-Jun N Terminal Kinases (JNK) in Cerebral Ischemia-Reperfusion-Injured Rats |
| Q38889427 | Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells. |
| Q38672607 | Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment |
Search more.